Compare Incyte Corporation (INCY) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Orion Office REIT Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Orion Office REIT Inc trades at $2.17 (market cap $125.50M). The key difference: Incyte Corporation is far larger — about 182.1× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Orion Office REIT Inc for 33 Days on average.
| INCY | ONL | |
|---|---|---|
Market Cap | $22.85B | $125.50M |
Volume | 1,927,029 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $129.93 | $3.00 |
52-Week Low | $83.80 | $1.93 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $18.35B | $542.43M |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
ONL trades at $2.20, down 3.08% today, with a bearish technical signal. The company shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics appear attractive with P/S of 0.88 and P/B of 0.2, but negative profitability metrics and high debt levels pose concerns. Recent news highlights strategic portfolio repositioning efforts.
Outlook remains challenging with ongoing revenue declines and negative margins, though deep valuation discounts may attract value investors. Key risks include high leverage, office sector exposure, and sustained profitability challenges. Analyst sentiment is mixed with 50% buy and 50% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
